Regeneron Casimvy Gene Therapy from Japan
Casimvy uses CRISPR/Cas9 ex vivo to edit CD34+ cells for sickle cell disease, administered as immunological cell therapy. As a measured-dose biotech product for retail, it fits HTS 3002.15.00.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Patient-specific autologous cells; donor matching documentation
• Cryopreserved transport (-196°C); liquid nitrogen shipper validation
• Distinguish from 3002.90 cell cultures if not therapeutically modified